Breaking: Landmark LSD Trial Could Reshape Psychedelics Landscape

Definium Therapeutics has announced positive topline results from its Phase 3 study of LSD (DT120) for major depressive disorder. This marks the first successful Phase 3 data for LSD, signaling a significant step toward potential medical approval. Merchants should monitor this development closely, as successful drug development could lead to future re-scheduling or changes in federal and state psychedelics legislation.